Annual report pursuant to Section 13 and 15(d)

Balance Sheet Components

v3.24.1
Balance Sheet Components
12 Months Ended
Dec. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Components

NOTE 6—BALANCE SHEET COMPONENTS

Accrued liabilities comprise the following (in thousands):

    

December 31,
2023

    

December 31,
2022

Accrued liabilities:

  

General and administrative

  

$

225

$

855

Clinical trial related costs

3,574

1,327

Non-clinical research and manufacturing operations

  

404

1,779

Payroll related

  

60

4,828

Other accrued expenses

  

16

34

Total Accrued liabilities

  

$

4,279

$

8,823